Minimally Invasive Pelvic Exenteration in Vaginal or Cervical Cancer Recurrence

The aim of this clinical trial is to assess the oncologic safety of minimally invasive pelvic exenteration in patients with recurrence or persistence of cervical or vaginal cancer with pelvic location, suitable for pelvic exenteration according to the ESGO guidelines (European Society of Gynecological Oncology). The primary aim is to assess the 3-year disease-free survival (DFS). The secondary aim is to assess the 3-year overall survival (OS), the intraoperative and post-operative complication rate, and the patient's quality of life.

Trial Details

NCT ID
NCT06867445
Phase
NA
Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Minimally invasive pelvic exenteration
Locations (sample)
  • Rome, Italy|41.89193,12.51133

Key Eligibility Criteria

  • Diagnosis of recurrent or persistent vaginal or cervical cancer
  • Proven histological diagnosis of squamous carcinoma, adenocarcinoma or adenosquamous carcinoma
  • Isolated central pelvic recurrence
  • MRI-measured maximum tumor diameter ≤ 50 mm

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →